Table 1

Baseline characteristics of patients with pSS and healthy controls

	Total		Pfizer-Biontech (BNT162b2)		Astrazeneca (ChAdOx1 nCoV-19)		Moderna (mRNA-1273)		Janssen (Ad.26.COV2.S)
	pSS (n=67)	HC (n=33)	pSS (n=47)	HC (n=14)	pSS (n=13)	HC (n=5)	pSS (n=6)	HC (n=8)	pSS (n=1)	HC (n=6)
Gender (female)	58 (87)	33 (100)	40 (85)	14 (100)	12 (92)	5 (100)	5 (83)	8 (100)	1 (100)	6 (100)
Age	59 (51–67)*	41 (33–62)*	58 (49–69)	57 (37–68)	63 (61–66)	61 (48–64)	45 (35–56)	28 (26–39)	53	40 (34–46)
Hydroxychloroquine use	15 (22)	n/a	10 (21)	n/a	5 (38)	n/a	0	n/a	0	n/a
ESSDAI (total)	3 (1–4)†	n/a	3 (1–5)†	n/a	3 (2–5)	n/a	2 (0–4)†	n/a	2	n/a
ESSDAI <5	46 (78)		30 (75)		10 (77)		5 (100)		1 (100)
ESSDAI 5–14	13 (22)		10 (25)		3 (23)		0
ESSDAI ≥14	0		0		0		0
Physician GDA	2 (1–2)‡	n/a	2 (1–2)‡	n/a	2 (1–3)†	n/a	1 (1–2)§	n/a	1	n/a
ESSPRI (total)	6 (5–7)	n/a	6 (5–7)	n/a	6 (5–8)	n/a	7 (6–8)	n/a	3	n/a
Patient GDA	6 (5–7)	n/a	6 (5–7)	n/a	7 (6–8)	n/a	7 (6–8)	n/a	4	n/a
IgG (g/L)	13 (10–19)¶**	10 (10–13)¶**	13 (10–19)**	10 (10–14)‡	12 (9–16)‡	9 (–)§	11 (10–15)	11 (10–14)†	11	12 (9–13)
Anti-SSA positive	49 (73)	n/a	35 (74)	n/a	11 (85)	n/a	2 (33)	n/a	1	n/a
RF positive	34 (55)**	n/a	25 (58)**	n/a	7 (54)	n/a	1 (20)†	n/a	1	n/a

Data presented as median (IQR) or n (%).
ESSDAI, physician GDA and RF collected ≤1 year before first vaccination date.
*Significant difference (p<0.005) between pSS and HC group.
†10%–20%.
‡20%–30%.
§30%–40% missing data.
¶Significant difference (p<0.05) between pSS and HC group.
**1%–10%.
ESSDAI, EULAR Sjögren’s Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren’s Syndrome Patient Reported Index; GDA, global disease activity; HC, healthy controls; n/a, not applicable; pSS, primary Sjögren’s syndrome; RF, rheumatoid factor.